TL;DR
This study investigated two different aflibercept injection regimens (3+PRN and 5+PRN) for treating diabetic macular edema (DME). While both regimens effectively improved vision and reduced retinal thickness, the 5+PRN approach showed a significant advantage in maintaining visual stability and requiring fewer "as-needed" injections, suggesting a potentially more efficient and patient-friendly treatment strategy.
What Problem Does This Paper Address?
Diabetic macular edema (DME) is a serious complication of diabetes that can lead to significant vision loss. Current first-line treatments involve intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, with a common regimen being "3+PRN" (three initial injections followed by "pro re nata" or as-needed injections). However, this approach can lead to repeated injections, high costs, and potential patient non-compliance over time, with its long-term advantage not always being significant. There's a growing interest in exploring more intensive initial treatment strategies to achieve better and more stable outcomes. This paper aims to compare the efficacy and safety of two aflibercept injection regimens: the standard 3+PRN and a more intensive 5+PRN approach, to see if a more aggressive initial treatment can lead to better long-term results with fewer "as-needed" interventions.
Methods
The researchers conducted a retrospective analysis of 78 patients diagnosed with DME. These patients were divided into two groups of 39: a control group receiving the standard 3+PRN aflibercept regimen and a study group receiving a 5+PRN regimen. The 3+PRN regimen involved three initial monthly injections followed by as-needed injections. The 5+PRN regimen involved five initial monthly injections followed by as-needed injections.
Key outcome measures included:
- Best-corrected visual acuity (BCVA): Measured in letters at baseline and at 1, 3, 6, and 12 months post-treatment. The proportion of patients achieving a 10-letter and 15-letter improvement was also assessed.
- Central macular thickness (CMT): Measured using optical coherence tomography (OCT) at the same time points as BCVA.
- Injection frequency: The total number of injections and the number of "as-needed" injections during the PRN period were recorded.
- Incidence of ocular adverse events: Any complications related to the injections were documented.
Statistical analysis was performed using SPSS, with independent samples t-tests for between-group comparisons and paired t-tests for within-group comparisons. A p-value less than 0.05 was considered statistically significant.
Datasets
The study utilized data from 78 patients with diabetic macular edema admitted to the Eye Hospital Affiliated to Hebei Medical University, China, between January 2021 and December 2022. This represents a real-world clinical dataset rather than a newly introduced benchmark.
Key Insights and Ideas
- Aflibercept is effective for DME: Both regimens demonstrated significant improvements in visual acuity and reductions in retinal thickness, confirming aflibercept's role in managing DME.
- Initial intensity matters for stability: While overall visual acuity gains were similar between the groups, the 5+PRN regimen led to a significantly lower rate of visual acuity instability during the "as-needed" phase. This suggests that a more intensive initial treatment might establish a more robust therapeutic effect, leading to fewer fluctuations.
- Fewer "as-needed" injections: The 5+PRN group required fewer injections during the PRN period, which could translate to reduced treatment burden, lower costs, and improved patient compliance in the long run.
- Safety profile is comparable: Both regimens were found to be safe, with no significant differences in adverse events, including common issues like subconjunctival hemorrhage or transient elevated intraocular pressure.
Key Results
- Visual Acuity (BCVA): Both groups showed significant BCVA improvement at 3, 6, and 12 months compared to baseline (p < 0.05). However, there was no significant difference in BCVA between the two groups at any time point (p > 0.05). The proportion of patients achieving a 10-letter or 15-letter improvement in BCVA at 12 months was also similar between the groups.
- Retinal Thickness (CMT): Both groups experienced a significant reduction in CMT at all measured time points (p < 0.05) compared to baseline. No significant difference in CMT was observed between the groups at any time point (p > 0.05).
- Visual Acuity Instability: The study group (5+PRN) had a significantly lower rate of visual acuity instability during the PRN period (7.69%) compared to the control group (3+PRN) (25.64%) (p < 0.05).
- Injection Frequency: While the total number of injections was not significantly different between the groups (p > 0.05), the study group received significantly fewer injections during the PRN period (p < 0.05).
- Adverse Events: No significant differences in the incidence of ocular adverse events were observed between the two groups.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: The study involved a relatively small number of patients (78 total, 39 per group).
- Short Follow-up Period: The 12-month follow-up might not be long enough to fully capture long-term differences between the regimens.
They suggest that future work should involve:
- Larger, Multicenter Studies: To further validate the findings and increase generalizability.
- Longer Follow-up Periods: To better assess long-term efficacy and stability.
- Analysis of Different Regimens: To continue exploring the optimal injection strategies for DME.
Summary updated